Paul C Lorigan

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6642459/paul-c-lorigan-publications-by-year.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

231 papers	39,366 citations	60 h-index	198 g-index
256 ext. papers	46,194 ext. citations	8.2 avg, IF	6.47 L-index

#	Paper	IF	Citations
231	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.. *Journal of Clinical Oncology*, **2022**, JCO2101601	2.2	10
230	Circulating Tumour DNA in Melanoma-Clinic Ready?. *Current Oncology Reports*, **2022**, 24, 363	6.3	1
229	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.. *Journal of Clinical Oncology*, **2022**, JCO2101701	2.2	2
228	Cutaneous Melanoma in Older Adults with Frailty **2022**, 383-401		
227	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.. *Nature Medicine*, **2022**,	50.5	14
226	Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.. *European Journal of Cancer*, **2022**, 164, 62-69	7.5	0
225	Prognostic and predictive value of blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.. *European Journal of Cancer*, **2022**, 165, 97-112	7.5	0
224	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. *European Journal of Cancer*, **2021**, 158, 156-168	7.5	5
223	T cell immune awakening in response to immunotherapy is age-dependent.. *European Journal of Cancer*, **2021**, 162, 11-21	7.5	0
222	Reply to E. Hindi *Journal of Clinical Oncology*, **2021**, 39, 944-946	2.2	
221	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 655-664	21.7	9
220	Sunbed Use among 11- to 17-Year-Olds and Estimated Number of Commercial Sunbeds in England with Implications for a Buy-Back Scheme. *Children*, **2021**, 8,	2.8	2
219	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 643-654	21.7	58
218	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. *Lancet Oncology, The*, **2021**, 22, 836-847	21.7	33
217	The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. *Nature Communications*, **2021**, 12, 4098	17.4	14
216	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. *International Journal of Cancer*, **2021**, 149, 1926-1934	7.5	1
215	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors reply. *Lancet Oncology, The*, **2021**, 22, e343-e344	21.7	0

214	Patient engagement in melanoma research: from bench to bedside. *Future Oncology*, **2021**, 17, 3705-3716	3.66	0
213	Adjuvant immunotherapy: the sting in the tail. *European Journal of Cancer*, **2020**, 132, 207-210	7.5	13
212	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. *European Journal of Cancer*, **2020**, 130, 126-138	7.5	39
211	Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. *Nature Cancer*, **2020**, 1, 210-221	15.4	65
210	Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. *Nature Communications*, **2020**, 11, 853	17.4	10
209	Emergency presentations in patients treated with immune checkpoint inhibitors. *European Journal of Cancer*, **2020**, 130, 193-197	7.5	16
208	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncology*, **2020**, 6, 519-527	13.4	148
207	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. *Journal of Clinical Oncology*, **2020**, 38, 3925-3936	2.2	78
206	Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma. *ESMO Open*, **2020**, 5,	6	2
205	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). *European Journal of Cancer*, **2019**, 119, 168-178	7.5	32
204	Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. *European Journal of Cancer*, **2019**, 116, 207-215	7.5	26
203	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. *European Journal of Cancer*, **2019**, 116, 148-157	7.5	42
202	Enhanced Fatty Acid Scavenging and Glycerophospholipid Metabolism Accompany Melanocyte Neoplasia Progression in Zebrafish. *Cancer Research*, **2019**, 79, 2136-2151	10.1	12
201	Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system. *Journal of the American Academy of Dermatology*, **2019**, 80, 272-274	4.5	11
200	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *Lancet Oncology, The*, **2019** , 20, 1239-1251	21.7	425
199	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). *European Journal of Cancer*, **2019**, 121, 144-153	7.5	19
198	An open-label, multicentre safety study of vemurafenib in patients with BRAF-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. *European Journal of Cancer*, **2019**, 107, 175-185	7.5	7
197	Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma. *Ocular Immunology and Inflammation*, **2019**, 27, 1012-1015	2.8	7

196	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *New England Journal of Medicine*, **2018**, 378, 1789-1801	59.2	918
195	The role of nivolumab in melanoma. *Future Oncology*, **2018**, 14, 1241-1252	3.6	6
194	Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. *OncoImmunology*, **2018**, 7, e1433516	7.2	26
193	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. *European Journal of Cancer*, **2018**, 91, 116-124	7.5	54
192	Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. *ESMO Open*, **2018**, 3, e000317	6	9
191	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. *Journal of the National Cancer Institute*, **2018**, 110,	9.7	49
190	Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 582-590	6.1	32
189	25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. *British Journal of Cancer*, **2018**, 119, 793-800	8.7	8
188	Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. *Annals of Oncology*, **2018**, 29, 1843-1852	10.3	33
187	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. *Oncotarget*, **2018**, 9, 34617-34627	3.3	5
186	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. *European Journal of Cancer*, **2018**, 91, 168-170	7.5	23
185	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus InvestigatorS Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. *Journal of Clinical Oncology*, **2018**, 36, 383-390	2.2	273
184	Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab. *BMJ Case Reports*, **2018**, 2018,	0.9	9
183	Emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes. *Cancer*, **2018**, 124, 4731	6.4	4
182	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. *Journal of Clinical Oncology*, **2017**, 35, 226-235	2.2	302
181	Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?. *Nature Reviews Clinical Oncology*, **2017**, 14, 395-396	19.4	5
180	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. *Lancet Oncology, The*, **2017**, 18, 1116-1125	21.7	253
179	Reply to SComment on SEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyS *British Journal of Cancer*, **2017**, 116, e15	8.7	1

178	Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. *European Journal of Cancer*, **2017**, 83, 247-257	7.5	181
177	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet, The*, **2017**, 390, 1853-1862	40	703
176	The role for chemotherapy in the modern management of melanoma. *Melanoma Management*, **2017**, 4, 125-136	2.1	15
175	Adjuvant interferon- for the treatment of high-risk melanoma: An individual patient data meta-analysis. *European Journal of Cancer*, **2017**, 82, 171-183	7.5	114
174	Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. *Clinical Lung Cancer*, **2017**, 18, 68-76.e2	4.9	40
173	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 651-660	7.1	4
172	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). *Annals of Translational Medicine*, **2017**, 5, 390-390	3.2	78
171	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.. *Journal of Clinical Oncology*, **2017**, 35, 9501-9501	2.2	6
170	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. *Journal of Clinical Oncology*, **2017**, 35, 9524-9524	2.2	14
169	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 651-660	7.1	6
168	Nivolumab in treating advanced melanoma. *British Journal of Health Care Management*, **2016**, 22, 294-296	.4	
167	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2016**, 34, 3740-3748	2.2	319
166	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. *Journal of Translational Medicine*, **2016**, 14, 65	8.5	8
165	Sequential immunotherapy regimens-expect the unexpected. *Lancet Oncology, The*, **2016**, 17, 854-855	21.7	6
164	Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis. *Practical Radiation Oncology*, **2016**, 6, 110-3	2.8	3
163	Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. *Investigational New Drugs*, **2016**, 34, 290-9	4.3	41
162	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. *Cancer Discovery*, **2016**, 6, 286-99	24.4	172
161	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. *European Journal of Cancer*, **2016**, 53, 125-34	7.5	115

160	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 36, e505-e514	7.1	9
159	Hyponatraemia secondary to nivolumab-induced primary adrenal failure. *Endocrinology, Diabetes and Metabolism Case Reports*, **2016**, 2016,	1.4	44
158	Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. *Oncotarget*, **2016**, 7, 81995-82012	3.3	10
157	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, e505-14	7.1	7
156	Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. *BMJ Open*, **2016**, 6, e009849	3	32
155	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. *Drugs*, **2016**, 76, 925-45	12.1	100
154	The place of PD-1 inhibitors in melanoma management. *Lancet Oncology, The*, **2015**, 16, 873-4	21.7	5
153	Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma. *Supportive Care in Cancer*, **2015**, 23, 779-89	3.9	32
152	Pembrolizumab versus Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2015**, 372, 2521-32	59.2	3792
151	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 375-84	21.7	1881
150	PD-L1 expression as a potential predictive biomarker. *Lancet Oncology, The*, **2015**, 16, 1285-7	21.7	75
149	Improved overall survival in melanoma with combined dabrafenib and trametinib. *New England Journal of Medicine*, **2015**, 372, 30-9	59.2	1723
148	Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. *Annals of Oncology*, **2015**, 26, 33-39	10.3	50
147	Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. *Melanoma Research*, **2015**, 25, 432-42	3.3	47
146	Dabrafenib and its use in the treatment of metastatic melanoma. *Melanoma Management*, **2015**, 2, 199-208	2.8	5
145	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. *Nature Medicine*, **2015**, 21, 741-50	50.5	75
144	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. *Lung Cancer*, **2015**, 88, 117-23	5.9	35
143	Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. *Cancer Cell*, **2015**, 27, 85-96	24.3	147

142	Expanded access programmes: patient interests versus clinical trial integrity. *Lancet Oncology, The*, **2015**, 16, 15-7	21.7	9
141	DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. *Annals of Oncology*, **2014**, 25, 968-74	10.3	53
140	Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. *British Journal of Dermatology*, **2014**, 170, 87-95	4	11
139	No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. *Molecular Oncology*, **2014**, 8, 1140-58	7.9	39
138	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. *Cancer Immunology, Immunotherapy*, **2014**, 63, 449-58	7.4	207
137	Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. *Journal of Clinical Oncology*, **2014**, 32, 185-90	2.2	34
136	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncology, The*, **2014**, 15, 323-32	21.7	753
135	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. *Lancet Oncology, The*, **2014**, 15, 620-30	21.7	78
134	The role of chemotherapy in the modern management of melanoma. *Melanoma Management*, **2014** , 1, 173-184	2.1	1
133	Vemurafenib-induced nonautoimmune haemolytic anaemia. *Melanoma Research*, **2014**, 24, 418-9	3.3	1
132	A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus InvestigatorS Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy. *Annals of Oncology*, **2014**, 25, v1	10.3	31
131	BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. *Science Signaling*, **2014**, 7, ra30	8.8	95
130	Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. *Annals of Oncology*, **2014**, 25, 2052-2058	10.3	46
129	Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. *Journal of Clinical Oncology*, **2014**, 32, 4012-9	2.2	197
128	Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. *Cancer Research*, **2014**, 74, 6390-6396	10.1	26
127	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. *Cancer*, **2014**, 120, 2016-24	6.4	15
126	Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. *Melanoma Research*, **2014**, 24, 40-6	3.3	61
125	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. *Lancet Oncology, The*, **2014**, 15, 297-304	21.7	49

124	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. *Cancer Chemotherapy and Pharmacology*, **2013**, 71, 1191-9	3.5	141
123	Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. *Journal of Investigative Dermatology*, **2013**, 133, 1582-90	4.3	107
122	Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. *Journal of Clinical Oncology*, **2013**, 31, 616-22	2.2	607
121	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. *Cancer Discovery*, **2013**, 3, 158-67	24.4	249
120	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. *Lancet Oncology, The*, **2013**, 14, 733-40	21.7	135
119	Urgent treatment of patients with metastatic melanoma using Braf inhibitors in the absence of Braf mutation status. *Annals of Oncology*, **2013**, 24, 1712-3	10.3	2
118	Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). *Annals of Oncology*, **2013**, 24, 2694-2698	10.3	119
117	Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. *British Journal of Cancer*, **2013**, 109, 1451-9	8.7	23
116	Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma.. *Journal of Clinical Oncology*, **2013**, 31, 9027-9027	2.2	3
115	DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma.. *Journal of Clinical Oncology*, **2013**, 31, 9068-9068	2.2	6
114	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.. *Journal of Clinical Oncology*, **2013**, 31, LBA9000-LBA9000	2.2	4
113	AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.. *Journal of Clinical Oncology*, **2013**, 31, LBA9000-LBA9000	2.2	
112	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. *Expert Review of Anticancer Therapy*, **2012**, 12, 1437-48	3.5	21
111	Considerations in developing and delivering a non-pharmacological intervention for symptom management in lung cancer: the views of health care professionals. *Supportive Care in Cancer*, **2012**, 20, 2565-74	3.9	16
110	Considerations in developing and delivering a nonpharmacological intervention for symptom management in lung cancer: the views of patients and informal caregivers. *Journal of Pain and Symptom Management*, **2012**, 44, 831-42	4.8	32
109	Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). *European Journal of Cancer*, **2012**, 48, 2175-82	7.5	32
108	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. *Health and Quality of Life Outcomes*, **2012**, 10, 66	3	45
107	Management of small cell lung cancer: recent developments for optimal care. *Drugs*, **2012**, 72, 471-90	12.1	52

106	Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study). *European Journal of Cancer*, **2012**, 48, 3205-14	7.5	22
105	Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial. *Lung Cancer*, **2012**, 76, 72-7	5.9	23
104	Applying Best-Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. *Lung Cancer*, **2012**, 77, 199-204	5.9	20
103	Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. *Lung Cancer*, **2012**, 78, 276-81	5.9	21
102	Improved survival with MEK inhibition in BRAF-mutated melanoma. *New England Journal of Medicine*, **2012**, 367, 107-14	59.2	1634
101	Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. *Oncologist*, **2012**, 17, 1376-85	5.7	21
100	Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. *Annals of Oncology*, **2012**, 23, 1723-9	10.3	21
99	Efficacy of positron emission tomography staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting. *Journal of Thoracic Oncology*, **2012**, 7, e25; author reply e26	8.9	
98	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. *Journal of Clinical Oncology*, **2012**, 30, 8502-8502	2.2	65
97	Anti-Angiogenesis Therapy for Melanoma **2012**, 281-294		
96	A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. *Journal of Clinical Oncology*, **2012**, 30, TPS8605-TPS8605	2.2	
95	A qualitative exploration of a respiratory distress symptom cluster in lung cancer: cough, breathlessness and fatigue. *Lung Cancer*, **2011**, 71, 94-102	5.9	72
94	Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. *Lung Cancer*, **2011**, 72, 378-83	5.9	46
93	Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. *Lung Cancer*, **2011**, 73, 338-44	5.9	4
92	Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. *Lung Cancer*, **2011**, 74, 75-9	5.9	14
91	The role of positron emission tomography in management of small cell lung cancer. *Lung Cancer*, **2011**, 73, 121-6	5.9	30
90	Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. *European Journal of Cancer*, **2011**, 47, 2322-30	7.5	27
89	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *New England Journal of Medicine*, **2011**, 364, 2507-16	59.2	5851

88	A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. *British Journal of Cancer*, **2011**, 104, 750-5	8.7	99
87	Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. *Melanoma Research*, **2011**, 21, 502-8	3.3	19
86	Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis. *Journal of Thoracic Oncology*, **2011**, 6, 1993-2004	8.9	64
85	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. *British Journal of Cancer*, **2011**, 105, 353-9	8.7	39
84	A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. *British Journal of Cancer*, **2011**, 105, 346-52	8.7	91
83	Revised U.K. guidelines for the management of cutaneous melanoma 2010. *British Journal of Dermatology*, **2010**, 163, 238-56	4	259
82	Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. *Clinical Cancer Research*, **2010**, 16, 1042-8	12.9	201
81	Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. *Journal of Clinical Oncology*, **2010**, 28, 2598-603	2.2	101
80	The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. *Annals of Oncology*, **2010**, 21, 2023-2028	10.3	60
79	The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. *Annals of Oncology*, **2010**, 21, 232-237	10.3	27
78	Revised UK guidelines for the management of cutaneous melanoma 2010. *Journal of Plastic, Reconstructive and Aesthetic Surgery*, **2010**, 63, 1401-19	1.7	92
77	Improved survival with ipilimumab in patients with metastatic melanoma. *New England Journal of Medicine*, **2010**, 363, 711-23	59.2	10591
76	Lung cancer after treatment for breast cancer. *Lancet Oncology, The*, **2010**, 11, 1184-92	21.7	25
75	Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. *Cancer Immunology, Immunotherapy*, **2010**, 59, 863-73	7.4	43
74	Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. *Journal of Clinical Oncology*, **2009**, 27, 4787-92	2.2	136
73	Targeting angiogenesis in melanoma. *Expert Review of Dermatology*, **2009**, 4, 237-248		
72	O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. *British Journal of Cancer*, **2009**, 100, 1250-6	8.7	35
71	Extensive-stage small-cell lung cancer--moving beyond response rate?. *Annals of Oncology*, **2009**, 20, 801-2	10.3	2

70	Radiotherapy in extensive-disease small cell lung cancer. A survey of current UK practice. *Clinical Oncology*, **2009**, 21, 78	2.8	4
69	Radiotherapy for small-cell lung cancer-Where are we heading?. *Lung Cancer*, **2009**, 63, 307-14	5.9	31
68	Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. *Lung Cancer*, **2009**, 64, 60-5	5.9	22
67	Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. *American Journal of Pathology*, **2009**, 175, 808-16	5.8	191
66	Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. *Pigment Cell and Melanoma Research*, **2009**, 22, 532-43	4.5	2
65	Prise en charge du cancer bronchique □petites cellules (CPC) (localis□et □endu). *Revue Des Maladies Respiratoires Actualites*, **2009**, 1, 436-443	0	
64	Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. *Melanoma Research*, **2009**, 19, 333-4	3.3	26
63	A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update. *Ecancermedicalscience*, **2008**, 2, 108	2.7	6
62	Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. *British Journal of Cancer*, **2008**, 99, 442-7	8.7	39
61	510 POSTER Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours. *European Journal of Cancer, Supplement*, **2008**, 6, 162	1.6	2
60	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. *Lancet, The*, **2008**, 372, 117-126	40	496
59	Update on targeted therapies for small cell carcinoma of the lung. *Targeted Oncology*, **2008**, 3, 205-215	5	1
58	A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. *Supportive Care in Cancer*, **2008**, 16, 201-8	3.9	79
57	Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?. *Experimental Dermatology*, **2008**, 17, 383-94	4	42
56	Modern management of small-cell lung cancer. *Drugs*, **2007**, 67, 2135-52	12.1	33
55	Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. *British Journal of Haematology*, **2007**, 137, 436-42	4.5	5
54	Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial. *Expert Review of Anticancer Therapy*, **2007**, 7, 635-40	3.5	3
53	Does adjuvant vaccine therapy really have activity in malignant melanoma?. *Journal of Clinical Oncology*, **2007**, 25, 4693; author reply 4693-5	2.2	23

52	Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. *Journal of Clinical Oncology*, **2007**, 25, 3144-50	2.2	209
51	Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. *Journal of Clinical Oncology*, **2007**, 25, 5426-34	2.2	225
50	Small Cell Lung Cancer (SCLC); any progress?. *European Journal of Cancer, Supplement*, **2007**, 5, 398-399	1.6	
49	A Review of the Treatment Strategies for Small Cell Lung Carcinoma Patients with a Poor Performance Status. *Current Respiratory Medicine Reviews*, **2006**, 2, 59-66	0.3	1
48	Melanoma vaccines--they should work. *Annals of Oncology*, **2006**, 17, 539-41	10.3	3
47	A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). *Annals of Oncology*, **2006**, 17, 1111-8	10.3	50
46	Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism?. *Drugs*, **2006**, 66, 1919-31	12.1	12
45	Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. *Lung Cancer*, **2006**, 53, 165-70	5.9	1
44	Sodium salicylate inhibits TNF-alpha-induced NF-kappaB activation, cell migration, invasion and ICAM-1 expression in human melanoma cells. *Melanoma Research*, **2006**, 16, 11-22	3.3	25
43	Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. *British Journal of Cancer*, **2006**, 95, 822-8	8.7	121
42	Re: Small cell lung cancer treated in southeast Wales, Lester et al., Clin Oncol 2006;18:378-382. *Clinical Oncology*, **2006**, 18, 722-3	2.8	
41	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. *Lancet Oncology, The*, **2005**, 6, 773-9	21.7	71
40	Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients. *European Journal of Cancer, Supplement*, **2005**, 3, 41-50	1.6	
39	Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. *Journal of Clinical Oncology*, **2005**, 23, 576-84	2.2	350
38	A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. *European Journal of Cancer*, **2005**, 41, 1547-50	7.5	10
37	Improving outcomes in advanced malignant melanoma: update on systemic therapy. *Drugs*, **2005**, 65, 733-43	12.1	31
36	Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions. *Clinical Lung Cancer*, **2005**, 7, 23-9	4.9	16
35	Thoracic radiotherapy for limited-stage small-cell lung cancer: controversies and future developments. *Clinical Oncology*, **2005**, 17, 591-8	2.8	20

34	Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status . *Journal of Clinical Oncology*, **2005**, 23, 2136-44	2.2	29
33	Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer. *Clinical Cancer Research*, **2005**, 11, 5051s-5056s	12.9	9
32	Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. *Journal of the National Cancer Institute*, **2005** , 97, 666-74	9.7	73
31	High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. *British Journal of Cancer*, **2005**, 93, 620-1	8.7	35
30	Management of small-cell lung cancer. *Annals of Oncology*, **2005**, 16 Suppl 2, ii235-9	10.3	35
29	Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. *Journal of Clinical Oncology*, **2004**, 22, 53-61	2.2	189
28	Palliative treatment. *Hematology/Oncology Clinics of North America*, **2004**, 18, 417-32	3.1	1
27	TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. *British Journal of Cancer*, **2003**, 89, 1123-9	8.7	61
26	Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma. *British Journal of Cancer*, **2003**, 88, 1335-8	8.7	5
25	Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. *Journal of Clinical Oncology*, **2003**, 21, 2551-7	2.2	99
24	Monitoring tumour cells in the peripheral blood of small cell lung cancer patients. *Cytometry*, **2002**, 50, 160-7		45
23	Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone. *Journal of Investigative Dermatology*, **2002**, 119, 1165-71	4.3	36
22	Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. *British Journal of Haematology*, **2002**, 116, 291-8	4.5	60
21	Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. *Clinical Oncology*, **2002**, 14, 361-6	2.8	24
20	A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST). *Sarcoma*, **2002**, 6, 83-7	3.1	9
19	Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. *Cancer*, **2001**, 92, 601-8	6.4	44
18	Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. *British Journal of Cancer*, **2001**, 84, 499-503	8.7	48
17	Gender and survival in malignant tumours. *Cancer Treatment Reviews*, **2001**, 27, 201-9	14.4	44

16	Oestrogenic steroids and melanoma cell interaction with adjacent skin cells influence invasion of melanoma cells in vitro. *Pigment Cell & Melanoma Research*, **2000**, 13 Suppl 8, 68-72		7
15	Guidelines for the stratification of patients recruited to trials of therapy for low-risk gestational trophoblastic tumor. *Gynecologic Oncology*, **2000**, 78, 92-6	4.9	11
14	Characteristics of women with recurrent molar pregnancies. *Gynecologic Oncology*, **2000**, 78, 288-92	4.9	39
13	Investigation of female survival benefit in metastatic melanoma. *British Journal of Cancer*, **1999**, 80, 2025-33	8.7	44
12	Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. *British Journal of Cancer*, **1999**, 81, 1037-41	8.7	20
11	Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. *European Journal of Cancer*, **1999**, 35, 410-2	7.5	58
10	Monitoring neutrophil phagocytosis in lung cancer patients or normal stem cell donors, treated with G-CSF. *Biochemical Society Transactions*, **1997**, 25, 197S	5.1	
9	Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate. *British Journal of Cancer*, **1997**, 76, 1382-6	8.7	9
8	Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA. *Cancer Letters*, **1996**, 104, 27-30	9.9	20
7	Current drug treatment guidelines for epithelial ovarian cancer. *Drugs*, **1996**, 51, 571-84	12.1	12
6	Small cell carcinoma of the cervix. *Clinical Oncology*, **1996**, 8, 102-5	2.8	10
5	MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy. *Leukemia and Lymphoma*, **1995**, 18, 297-302	1.9	8
4	Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma. *British Journal of Cancer*, **1995**, 72, 193-7	8.7	2
3	Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. *European Journal of Cancer*, **1994**, 30A, 2085-90	7.5	10
2	Septicaemia and septic arthritis due to Pseudomonas putida in a neutropenic patient. *Journal of Infection*, **1991**, 23, 346-7	18.9	10
1	DGAT1 is a lipid metabolism oncoprotein that enables cancer cells to accumulate fatty acid while avoiding lipotoxicity		1